NO20013507L - Blandinger for behandling av inflammatoriske reaksjoner - Google Patents

Blandinger for behandling av inflammatoriske reaksjoner

Info

Publication number
NO20013507L
NO20013507L NO20013507A NO20013507A NO20013507L NO 20013507 L NO20013507 L NO 20013507L NO 20013507 A NO20013507 A NO 20013507A NO 20013507 A NO20013507 A NO 20013507A NO 20013507 L NO20013507 L NO 20013507L
Authority
NO
Norway
Prior art keywords
preparations
treatment
inflammatory reactions
inflammatory
reactions
Prior art date
Application number
NO20013507A
Other languages
English (en)
Other versions
NO321216B1 (no
NO20013507D0 (no
Inventor
Joel M Linden
Gail W Sullivan
Ian J Sarembock
Timothy Macdonald
Mark Okusa
Irving L Kron
Michael W Scheld
Original Assignee
Univ Virginia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/333,387 external-priority patent/US6232297B1/en
Application filed by Univ Virginia filed Critical Univ Virginia
Publication of NO20013507D0 publication Critical patent/NO20013507D0/no
Publication of NO20013507L publication Critical patent/NO20013507L/no
Publication of NO321216B1 publication Critical patent/NO321216B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/167Purine radicals with ribosyl as the saccharide radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20013507A 1999-02-01 2001-07-13 Blandinger for behandling av inflammatoriske reaksjoner NO321216B1 (no)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11802999P 1999-02-01 1999-02-01
US12431699P 1999-03-12 1999-03-12
US13337499P 1999-05-10 1999-05-10
US13557399P 1999-05-24 1999-05-24
US09/333,387 US6232297B1 (en) 1999-02-01 1999-06-15 Methods and compositions for treating inflammatory response
US15141299P 1999-08-30 1999-08-30
PCT/US2000/002324 WO2000044763A2 (en) 1999-02-01 2000-01-31 Compositions for treating inflammatory response

Publications (3)

Publication Number Publication Date
NO20013507D0 NO20013507D0 (no) 2001-07-13
NO20013507L true NO20013507L (no) 2001-09-18
NO321216B1 NO321216B1 (no) 2006-04-03

Family

ID=27557920

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013507A NO321216B1 (no) 1999-02-01 2001-07-13 Blandinger for behandling av inflammatoriske reaksjoner

Country Status (26)

Country Link
EP (1) EP1150991B1 (no)
JP (1) JP4837831B2 (no)
KR (1) KR100668006B1 (no)
CN (1) CN1191266C (no)
AR (1) AR029332A1 (no)
AT (1) ATE263777T1 (no)
AU (2) AU778870B2 (no)
BR (1) BR0007864A (no)
CA (1) CA2361614C (no)
CZ (1) CZ296404B6 (no)
DE (1) DE60009665T2 (no)
DK (1) DK1150991T3 (no)
EE (1) EE05185B1 (no)
ES (1) ES2215609T3 (no)
HK (1) HK1047288A1 (no)
HU (1) HU228937B1 (no)
IL (2) IL144188A0 (no)
MX (1) MXPA01007850A (no)
MY (1) MY129445A (no)
NO (1) NO321216B1 (no)
NZ (1) NZ513096A (no)
PL (1) PL199953B1 (no)
PT (1) PT1150991E (no)
SK (1) SK284877B6 (no)
UA (1) UA72912C2 (no)
WO (1) WO2000044763A2 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6322771B1 (en) * 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
WO2003029264A2 (en) 2001-10-01 2003-04-10 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
US20050033044A1 (en) 2003-05-19 2005-02-10 Bristol-Myers Squibb Pharma Company Methods for preparing 2-alkynyladenosine derivatives
EP1740587A4 (en) * 2004-04-02 2009-07-15 Adenosine Therapeutics Llc SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS
US7396825B2 (en) * 2004-05-03 2008-07-08 University Of Virginia Patent Foundation Agonists of A2A adenosine receptors for treatment of diabetic nephropathy
WO2006023272A1 (en) 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
WO2006028618A1 (en) 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
EP1778712B1 (en) * 2004-08-02 2013-01-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
US8178509B2 (en) 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
US20100048501A1 (en) 2006-03-21 2010-02-25 Heinrich-Heine-Universitat Dusseldorf Phosphorylated A2A Receptor Agonists
US8188063B2 (en) 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
US20100003193A1 (en) 2008-07-03 2010-01-07 University Of Virginia Patent Foundation Unit dosage of apadenoson
US8263762B2 (en) 2009-06-30 2012-09-11 Dogwood Pharmaceuticals, Inc. Alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof as A2AR agonists
FR2960876B1 (fr) 2010-06-03 2012-07-27 Sanofi Aventis Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.
JP2022538410A (ja) * 2019-06-21 2022-09-02 アカデミー オブ ミリタリー メディカル サイエンシズ A2aアデノシン受容体拮抗作用を有する小分子化合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3537228A1 (de) * 1985-10-19 1987-04-23 Huels Chemische Werke Ag Verfahren zur herstellung von cyclohexylverbindungen
JPS6299330A (ja) * 1985-10-25 1987-05-08 Yamasa Shoyu Co Ltd 抗高血圧剤
US5270304A (en) * 1988-11-15 1993-12-14 Yamasa Shoyu Kabushiki Kaisha Therapeutic 2-alkynyl adenosine agent for ischemic diseases of the heart or brain
ES2077070T3 (es) * 1989-06-20 1995-11-16 Yamasa Shoyu Kk Intermedio de sintesis de 2-alquiniladenosina, produccion de dicho intermedio, produccion de 2-alquiniladenosina a partir de dicho intermedio, y derivado de 2-alquiniladenosina estable.
WO1991009864A1 (en) * 1990-01-04 1991-07-11 Yamasa Shoyu Kabushiki Kaisha Drug for treating or preventing ischemic diseases of heart or brain
JPH03287537A (ja) * 1990-03-31 1991-12-18 Yamasa Shoyu Co Ltd 抗動脈硬化症剤
JP3025559B2 (ja) * 1990-07-19 2000-03-27 ヤマサ醤油株式会社 アデノシン誘導体
JP3053908B2 (ja) * 1991-06-28 2000-06-19 ヤマサ醤油株式会社 2‐アルキニルアデノシン誘導体
JP3025557B2 (ja) * 1991-06-28 2000-03-27 ヤマサ醤油株式会社 2‐アルキニルアデノシン誘導体
IT1254915B (it) * 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
AU7449598A (en) * 1997-05-23 1998-12-11 Nippon Shinyaku Co. Ltd. Medicinal composition for prevention or treatment of hepatopathy
EP1014995A4 (en) * 1997-06-18 2005-02-16 Aderis Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSES CONSECUTIVE TO REVASCULARIZATION INTERVENTIONS
JPH11335302A (ja) * 1998-05-26 1999-12-07 Toa Eiyo Ltd 安定な医薬組成物
JP3619017B2 (ja) * 1998-06-24 2005-02-09 日本臓器製薬株式会社 新規アラビノシルアデニン誘導体
JP2002173427A (ja) * 1998-09-01 2002-06-21 Yamasa Shoyu Co Ltd 眼疾患治療用医薬組成物

Also Published As

Publication number Publication date
PT1150991E (pt) 2004-08-31
CZ296404B6 (cs) 2006-03-15
BR0007864A (pt) 2001-11-06
CA2361614C (en) 2008-08-26
DK1150991T3 (da) 2004-06-07
CA2361614A1 (en) 2000-08-03
ES2215609T3 (es) 2004-10-16
NO321216B1 (no) 2006-04-03
ATE263777T1 (de) 2004-04-15
HK1047288A1 (en) 2003-02-14
AU2745400A (en) 2000-08-18
MY129445A (en) 2007-04-30
CN1357002A (zh) 2002-07-03
CZ20012781A3 (cs) 2002-01-16
JP2002536300A (ja) 2002-10-29
UA72912C2 (uk) 2005-05-16
MXPA01007850A (es) 2002-08-20
KR100668006B1 (ko) 2007-01-15
WO2000044763A2 (en) 2000-08-03
AR029332A1 (es) 2003-06-25
DE60009665D1 (de) 2004-05-13
SK10972001A3 (sk) 2002-01-07
CA2361614E (en) 2000-08-03
IL144188A0 (en) 2002-05-23
HU228937B1 (en) 2013-06-28
EE05185B1 (et) 2009-06-15
WO2000044763A3 (en) 2000-12-14
JP4837831B2 (ja) 2011-12-14
NZ513096A (en) 2003-01-31
KR20020013494A (ko) 2002-02-20
AU2005201255A1 (en) 2005-04-21
IL144188A (en) 2008-12-29
EE200100397A (et) 2002-08-15
PL199953B1 (pl) 2008-11-28
DE60009665T2 (de) 2004-08-19
SK284877B6 (sk) 2006-01-05
AU2005201255B2 (en) 2008-02-28
HUP0200224A3 (en) 2005-02-28
CN1191266C (zh) 2005-03-02
AU778870B2 (en) 2004-12-23
EP1150991A2 (en) 2001-11-07
HUP0200224A2 (en) 2002-06-29
EP1150991B1 (en) 2004-04-07
NO20013507D0 (no) 2001-07-13

Similar Documents

Publication Publication Date Title
NO20013507L (no) Blandinger for behandling av inflammatoriske reaksjoner
NO20013369D0 (no) Arylpiperazinyl-cykloheksyl-indol-derivater for behandling av depresjon
NO20021474D0 (no) Forbindelser for behandling av ischemi
NO20014379D0 (no) Anvendelse av Xenon for behandling av Neurointoksikasjoner
NO20012995L (no) Forbindelser nyttige for behandling av inflammatoriske sykdommer
DK1637127T3 (da) Terapeutisk mikroskum
EE200100536A (et) Amiini-plaatina komplekside valmistamismeetod
FI20000863A (fi) Uusi hoitomenetelmä
NO20022087D0 (no) Fremgangsmåte for behandling av diabetes
NO20015542L (no) Fremgangsmåte for fremstilling og anvendelse av N- desmetylzopikloner
DK1176964T3 (da) Brug af ET743 til behandling af cancer
NO20022245D0 (no) Onkolyttiske kombinasjoner for behandling av cancer
HUP0201038A2 (en) Preparations for the application of anti-inflammatory agents
NO20024777L (no) Kinolinyl-piperidin-4-yliden-metyl-benzamid derivater til behandling av smerte
NO20024776D0 (no) Hydroksyfenyl-piperazinyl-metyl-benzamidderivater til behandling av smerte
NO20012541D0 (no) Anvendelse av fosfonomaursyrederivater for behandling av infeksjoner
NO20012612L (no) Isonipecotamider for behandlingen av integrin-formidlede sykdommer
DK1200447T3 (da) Oxazinocarbazoler til behandling af CNS-sygdomme
NO20014845D0 (no) Anvendelse av arylalkanoylpyridaziner
NO20012540D0 (no) Anvendelse av fosfonomaursyrederivater for behandling av infeksjoner
IS2153B (is) S-nítrósóþíól til meðferðar við blóðrásartruflunum
NO20020328D0 (no) Fremgangsmåte for fremstilling av 4-cyano-2-aminometyltiazol
PT1232141E (pt) Eteres de o-desmetil-venlafaxina
NO20011268D0 (no) Forbindelse til behandling av depresjon
NO996166L (no) FremgangsmÕte for behandling av avluter

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees